Clinical characteristics of enrolled patients
| Characteristic . | No. . | % . |
|---|---|---|
| Total | 28 | 100 |
| Median age at diagnosis, y (range) | 54 (31-69) | |
| Sex | ||
| Male | 23 | 82 |
| Female | 5 | 18 |
| IGHV mutational status | ||
| Mutated | 8 | 28 |
| Unmutated | 15 | 54 |
| Unknown | 5 | 18 |
| Zap70 | ||
| Negative | 9 | 32 |
| Positive | 14 | 50 |
| Unknown | 5 | 18 |
| FISH (by Dohner hierarchy) | ||
| del (17p) | 5 | 18 |
| del (11q) | 9 | 32 |
| Trisomy 12 | 0 | 0 |
| del (13q) | 10 | 36 |
| Normal | 4 | 14 |
| Karyotype | ||
| Complex, 5+ abnormalities | 7 | 25 |
| Complex, 3-4 abnormalities | 2 | 7 |
| Not complex (<3 abnormalities) | 9 | 32 |
| Unknown | 10 | 36 |
| Treatment history | ||
| Median time from diagnosis to sampling, y (range) | 7.9 (0.1-19.2) | |
| No. of treated patients at first sample | 26 | 93 |
| Median time from diagnosis to first treatment, y (range) | 2.0 (0-7.4) | |
| Median no. of previous treatments (range) | 4.5 (0-6) | |
| PI3K inhibitors used in this study | ||
| Idelalisib (PI3Kδ) | 22 | 78 |
| Pilaralisib (pan-PI3K) | 3 | 11 |
| Voxtalisib (pan-PI3K/mTOR) | 3 | 11 |
| Characteristic . | No. . | % . |
|---|---|---|
| Total | 28 | 100 |
| Median age at diagnosis, y (range) | 54 (31-69) | |
| Sex | ||
| Male | 23 | 82 |
| Female | 5 | 18 |
| IGHV mutational status | ||
| Mutated | 8 | 28 |
| Unmutated | 15 | 54 |
| Unknown | 5 | 18 |
| Zap70 | ||
| Negative | 9 | 32 |
| Positive | 14 | 50 |
| Unknown | 5 | 18 |
| FISH (by Dohner hierarchy) | ||
| del (17p) | 5 | 18 |
| del (11q) | 9 | 32 |
| Trisomy 12 | 0 | 0 |
| del (13q) | 10 | 36 |
| Normal | 4 | 14 |
| Karyotype | ||
| Complex, 5+ abnormalities | 7 | 25 |
| Complex, 3-4 abnormalities | 2 | 7 |
| Not complex (<3 abnormalities) | 9 | 32 |
| Unknown | 10 | 36 |
| Treatment history | ||
| Median time from diagnosis to sampling, y (range) | 7.9 (0.1-19.2) | |
| No. of treated patients at first sample | 26 | 93 |
| Median time from diagnosis to first treatment, y (range) | 2.0 (0-7.4) | |
| Median no. of previous treatments (range) | 4.5 (0-6) | |
| PI3K inhibitors used in this study | ||
| Idelalisib (PI3Kδ) | 22 | 78 |
| Pilaralisib (pan-PI3K) | 3 | 11 |
| Voxtalisib (pan-PI3K/mTOR) | 3 | 11 |
FISH, fluorescence in situ hybridization; mTOR, mammalian target of rapamycin.